GICS Sector : Healthcare
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington. Show Full description
Absci Corporation reported revenue of $400,000 for Q3 2025, with research and development expenses at $19.2 million and selling, general, and administrative expenses at $8.4 million. The company's EPS came in at -$0.2, slightly missing estimates of -$0.19. The cash, cash equivalents, and marketable securities stood at $152.5 million as of September 30, 2025, expected to fund operations into 2028. Analysts estimate a significant revenue growth of 463.0% for the next year, indicating a potential surge in the company's financial performance.
Publication Date: Nov -25
The company's financials indicate a significant investment in research and development, with expenses accounting for a substantial portion of the overall costs. The current valuation metrics show a P/E Ratio of -3.33, P/B Ratio of 2.18, and P/S Ratio of 107.56, indicating a potentially high valuation relative to sales. The EV/EBITDA ratio stands at -4.14, suggesting that the company's enterprise value is not justified by its current earnings before interest, taxes, depreciation, and amortization.
Absci Corporation made significant progress in its pipeline, with ABS-201 moving into the clinic. The company is accelerating the development of ABS-201 in androgenetic alopecia (AGA) and expanding its development in endometriosis. A phase 1/2a trial for AGA is set to initiate in December, with an interim proof of concept readout anticipated in 2026. The company also plans to initiate a phase two proof of concept clinical trial for endometriosis in 2026, leveraging the safety data from the AGA trial in a capital-efficient development plan.
The company's preclinical data supports the mechanism of ABS-201, which is designed to antagonize the prolactin receptor. The treatment has shown potential in treating both AGA and endometriosis, with the potential to be a safe and effective therapy for the estimated 10% of women globally who suffer from endometriosis. The company believes that the prolactin receptor antibody should work in every endometriosis patient, as there is increased prolactin receptor and prolactin expression in endometriosis lesions and sensory neurons.
The company plans to sign one or more drug creation partnerships, including with a large pharma company, by the end of the year. With its current balance sheet, Absci believes it is well-positioned to execute on its strategy and deliver potential proof of concept readouts for ABS-201 in both AGA and endometriosis. The company's focus remains on driving the program through phase 1/2a for AGA and phase 2 for endometriosis, with a potential expansion into additional indications in the future.
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
Dec -04
10 AI Stocks Worth Buying Right Now
Dec -04
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade
Dec -01
Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript
Nov -22
Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript
Nov -13
Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates
Nov -12
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
Nov -12
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
Oct -29
Absci Corporation's biologics segment growth of 10.55% is driven by increasing demand for novel therapeutic proteins, advancements in antibody engineering, and strategic partnerships. Additionally, the company's proprietary Bionic Protein platform enables rapid discovery and development of novel biologics, further fueling growth.
A novel, AI-driven protein design platform that enables the rapid design and optimization of therapeutic proteins
A proprietary protein design and optimization technology that leverages AI and machine learning to create novel protein therapeutics
A comprehensive platform that integrates AI-driven protein design, high-throughput screening, and machine learning-based lead optimization
A suite of technologies and services for the design, optimization, and production of novel therapeutic proteins
A platform for the rapid discovery and optimization of therapeutic antibodies
Absci Corporation's threat of substitutes is moderate due to the availability of alternative biotech companies that can provide similar services.
Absci Corporation's customers have limited bargaining power due to the company's unique technology and expertise in AI-driven biotech.
Absci Corporation's suppliers have moderate bargaining power due to the availability of alternative suppliers, but the company's strong relationships with its suppliers mitigate this risk.
The threat of new entrants is high in the biotech industry, as new companies can easily enter the market with innovative technologies and disrupt the existing landscape.
The intensity of rivalry in the biotech industry is high, with many established companies competing for market share and innovative breakthroughs.
| Value | |
|---|---|
| Debt Weight | 5.49% |
| Debt Cost | 6.32% |
| Equity Weight | 94.51% |
| Equity Cost | 16.03% |
| WACC | 15.49% |
| Leverage | 5.81% |
Value: 8.0
Growth: 4.2
Quality: 4.8
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 7.4
Growth: 4.4
Quality: 5.8
Yield: 0.0
Momentum: 5.0
Volatility: 0.7
1-Year Total Return ->
Value: 9.2
Growth: 5.8
Quality: 4.8
Yield: 0.0
Momentum: 0.0
Volatility: 1.7
1-Year Total Return ->
Value: 6.6
Growth: 2.7
Quality: 3.8
Yield: 0.0
Momentum: 2.5
Volatility: 1.0
1-Year Total Return ->
Value: 6.4
Growth: 5.7
Quality: 3.5
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->
Value: 7.2
Growth: 1.1
Quality: 4.4
Yield: 0.0
Momentum: 0.0
Volatility: 2.3
1-Year Total Return ->